Abstract Library

#4281 Automated (artificial intelligence) vs. manual evaluation of the somatostatin-receptor 2A and proliferation marker Ki-67 in neuroendocrine neoplasms: A pilot study

Introduction: Digital image analysis methods are currently being equipped with artificial intelligence (AI). Various AI applications are already in use to determine Ki-67. To date, there is no specialised AI application available to determine the somatostatin-receptor 2A (SSTR2A).

Conference:

Presenting Author:

Authors: Kaemmerer D, Lupp A, Klöppel G, Ayako I, Kasajima A,

Keywords: artificial intelligence, Ki-67, SSTR2A, usability, neuroendocrine neoplasm,

#3290 Intratumoral serotonin might decrease the efficacy of PRRT in ileal neuroendocrine tumors

Introduction: Partial remission can be achieved by peptide receptor radionuclide therapy (PRRT) in only roughly 20% of patients with midgut neuroendocrine tumor (NET). This low remission rate can be due to the radioprotective role of stored intracytoplasmic serotonin in NET cells. If blocked, e.g. by telotristatethyl, PRRT efficacy might be increased.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Prasad V, Klöppel G, Lupp A, Wirtz R, Kaemmerer D,

Keywords: Ileal NET, serotonin, radioprotector, PRRT, immunohistochemistry, TPH1,

#3167 Safety of Irinotecan-based chemotherapy as second-line treatment in extrapulmonary poorly differentiated neuroendocrine carcinomas (NECs)

Introduction: Owing to their low incidence, little evidence is available on the proper treatment of Neuroendocrine Carcinomas (NECs), a subgroup of tumors with scarce prognosis. Platinum plus Etoposide have been validated as first-line therapy since the 1991, while there is no consensus regarding further-lines treatment. Irinotecan (IRI)-based chemotherapy have shown promising results in second-line setting but data on safety are poor.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bardasi C

Authors: Bardasi C, Spallanzani A, Luppi G, Bertolini F, Fontana A,

Keywords: neuroendocrine carcinoma, Irinotecan, safety, second-line treatment, chemotherapy, NEC, adverse events,

#1723 Evaluation of the Somatostatin and CXCR4 Chemokine Receptor Expression in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of Different Origin

Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, whereas the chemokine receptor CXCR4 is considered to be present mainly in highly proliferative and advanced tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lupp A

Authors: Mai R, Kaemmerer D, Sänger J, Neubauer E, Schulz S,

Keywords: somatostatin receptor, CXCR4,

#1302 Differential Somatostatin and CXCR4 Chemokine Receptor Expression in Primary Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) and Their Metastases

Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, where they serve as molecular targets for different imaging and treatment modalities. The chemokine receptor CXCR4, in contrast, is present mainly in highly proliferative and advanced tumors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Kaemmerer D, Träger T, Sänger J, Schulz S, Lupp A,

Keywords: somatostatin receptor, chemokine receptor, sstr,